Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake

Rhea-AI Filing Summary

Harvard Bioscience reported a Schedule 13G/A amendment showing that Adam M. Hutt, as Managing Member of Leviticus Partners, beneficially owns 293,676 shares of Common Stock, representing 6.5% of the class. The filing lists sole voting and sole dispositive power over those shares.

The document provides the filer’s and issuer’s addresses and the CUSIP 416906105. A signature line shows the amendment signed on 05/14/2026.

Insights

Corporate Governance Specialist

Ownership disclosure shows a single holder with material but non‑control stake.

The filing identifies 293,676 shares held with sole voting and sole dispositive power, representing 6.5% of the class. This level can make the holder a meaningful minority shareholder but does not alone indicate control or an activist intent.

Key dependencies are the share count basis and any changes in subsequent amendments. Subsequent filings or public schedules would clarify whether the position changes materially.

Securities Compliance Analyst

Amendment updates beneficial ownership disclosures and power details.

The record shows the filer as Managing Member of the reporting entity and cites both issuer and filer addresses plus CUSIP 416906105. The document explicitly reports sole voting and sole dispositive powers for the same 293,676 shares.

Filing compliance appears routine: watch for any later Schedule 13D/A or Form 4 that would indicate activist intent or changes in ownership strategy.

Key Figures

Beneficial ownership: 293,676 shares Percent of class: 6.5% Sole voting power: 293,676 shares +3 more

6 metrics

Beneficial ownership 293,676 shares Amount beneficially owned reported on the Schedule 13G/A

Percent of class 6.5% Percent of class corresponding to 293,676 shares

Sole voting power 293,676 shares Number with sole power to vote as reported

Sole dispositive power 293,676 shares Number with sole power to dispose as reported

CUSIP 416906105 Identifier for Harvard Bioscience common stock

Signature date 05/14/2026 Date shown on the signed amendment

Key Terms

Schedule 13G/A, Beneficial ownership, Sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 7 ) HARVARD BIOSCIENCE INC"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership regulatory

"Amount beneficially owned: 293,676 (b) Percent of class: 6.5 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole dispositive power regulatory

"Sole Dispositive Power 293,676.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

HARVARD BIOSCIENCE INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

416906105

(CUSIP Number)

05/12/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 416906105

1

Names of Reporting Persons

Leviticus Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 293,676.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 293,676.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

293,676.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: HARVARD BIOSCIENCE INC
(b)	Address of issuer's principal executive offices: 84 OCTOBER HILL RD, 84 OCTOBER HILL RD, HOLLISTON, MASSACHUSETTS, 01746.
Item 2.
(a)	Name of person filing: Adam M Hutt
(b)	Address or principal business office or, if none, residence: 32 OLD MILL RD Great Neck, NY 11023
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 416906105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 293,676
(b)	Percent of class: 6.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 293,676
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 293,676
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Leviticus Partners LP

Signature:	Adam M Hutt
Name/Title:	Managing Member
Date:	05/14/2026

FAQ

What stake does Leviticus Partners hold in Harvard Bioscience (HBIO)?

Leviticus Partners, via Adam M. Hutt, reports beneficial ownership of 293,676 shares, equal to 6.5% of Harvard Bioscience's common stock. The disclosure lists both sole voting and sole dispositive power over those shares.

Who is the reporting person on the Schedule 13G/A for HBIO?

The reporting person is Adam M. Hutt, identified as Managing Member of Leviticus Partners. The filing provides his address at 32 OLD MILL RD, Great Neck, NY 11023 and a signature dated 05/14/2026.

Does the filing indicate whether Harvard Bioscience will receive proceeds from these shares?

The disclosure simply reports beneficial ownership and powers over 293,676 shares. It does not state any sale, offering, or proceeds; no proceeds treatment is described in the provided excerpt.

What voting and dispositive powers are reported for the HBIO shares?

The Schedule 13G/A states the reporting person has sole power to vote and sole power to dispose of 293,676 shares, with 0 shared voting or dispositive power reported.

What identifier and issuer details are included in the HBIO amendment?

The document lists the issuer as Harvard Bioscience Inc, CUSIP 416906105, and the issuer’s principal executive office at 84 October Hill Rd, Holliston, MA 01746.